A Phase 1 interventional study of Huperzine A injection and Huperzine A injection in Healthy Subjects, sponsored by Wanbangde Pharmaceutical Group Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Wanbangde Pharmaceutical Group Co., LTD · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study used a single-center, open, sequential single-dose design. To evaluate the pharmacokinetics and dose-exposure relationship of huperzine A injection
The study was divided into four modes of administration. Administration method of A: intravenous injection (non-blood collection arm), intravenous injection of 0.2mg huperzine A injection. B, C, D Administration methods: 0.1mg, 0.2mg, 0.4mg huperzine A injection was injected intramuscularly into the deltoid muscle of the upper arm (the arm on the non-blood collection side). In each cycle, after fasting for at least 10 hours, the subjects received different dosing regimens according to A sequential single dosing method, that is, each subject received dosing method A first, followed by dosing method B after the cleaning period, dosing method C after the cleaning period, and dosing method D after the cleaning period. The wash-out period between the two doses was 7 days for each subject. To evaluate the pharmacokinetics and dose-exposure relationship of huperzine A injection.
Wanbangde Pharmaceutical Group Co., LTD is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
use of any drugs that alter liver enzyme activity within 30 days before screening (e.g., inductors-barbiturates, carbamazepine, phenytoin, dexamethasone, etc.; \"Inhibitors - SSRI antidepressants, ciprofloxacin, diltiazem, macrolides, metronidazole, ketoconazole, verapamil.
Rice, fluoroquinolones);
have a fertility plan (including sperm and egg donation plans) and/or do not agree to use an effective method (non-drug during the trial) from the time of signing the until 3 months after the last dose of medication.
Of;
subjects may not be able to complete the study for other reasons or should not be included according to the investigator\'s opinion.
In addition to the above requirements, female subjects who meet the following conditions should also be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The same 12 subjects first received 0.2 mg single dose intravenously, then received intramuscular injection of single-dose 0.1 mg, followed by single-dose 0.2 mg, and finally single-dose 0.4 mg. A wash-out period of 7 days was applied between the doses.
Drug: Huperzine A injection
intramuscular
intravenous bolus
Pharmacokinetics (PK): Maximum blood concentration of Huperzine A(Cmax)
To measure the Cmax of Huperzine A in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK: Area under the Huperzine A blood concentration-time curve from 0min to the time of last concentration(AUC0-t)
To measure the AUC0-t of Huperzine A in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK:Area under the Huperzine A blood concentration-time curve from 0min to the infinity time (AUC0-∞)
To measure the AUC0-∞ of Huperzine A in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PD: maximum efficacy(Emax)
Emax is defined as the maximum activities of red blood cell acetylcholinesterase and calculated as the maximum difference between erythrocyte acetylcholinesterase and baseline value. It is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PD: Area under the efficacy curve(AUEC)
AUEC is defined as the area under the activity-time curve from 0min to the time of last sample collection, which is adjusted for baseline. It is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PD: Time to reach maximum efficacy(Tmax)
Tmax(PD) is defined as the time to peak activity of red blood cell acetylcholinesterase. It is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK: Time to peak maximum concentration of the Huperzine A(Tmax)
Tmax(PK) is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK: half life of Huperzine A(t1/2)
t1/2 is defined as the time to eliminate half blood concentration of Huperzine A and is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK: λz
λz is defined as the blood concentration elimination rate constant of terminal phase. It is obtained by semilog linear regression with at least 3 non-zero concentration points of the end elimination phase, and the result is the inverse of the slope. It is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK: Area under the curve(AUC_%Extrap)
AUC\_%Extrap is defined as the percentage of residual area which refers to the area under the Huerperzine A blood concentration-time curve. It is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK: Clearance(CL)
CL is defined as how many milliliters of Huperzine A in blood are eliminated per unit time, it is calculated by the fomula: CL=D/AUC0-∞ (D refers to the dosage of Huperzine A). It is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK:Apparent volume of distribution(Vd)
Vd is defined as the ratio of the amount of drug in the body to the concentration in the blood after the drug has reached homeostasis in the body. It is calculated by the fomula: Vd=CL/λz. It is measured in 4 different periods of sequential administration in 12 healthy subjects.
Time frame: Day1、Day8、Day15、Day22
PK:Bioavailability(F)
F is defined as the ratio of the AUC0-∞ of intramuscular administration and AUC0-∞ of intravenous administration
Time frame: Day1、Day8、Day15、Day22
Urine excretion of Huperzine A.(UE)
UE is defined as the amout of the Huperzine A excreted in urine during the specific time. It is calculated by the fomula: UE=Cut×Vut(Cut refers to concentration of Huperzine A excreted in urine, Vut refers to the volume of urine).
Time frame: Baseline、Day15-Day17
Cumulative urinary excretion of Huperzine A(CUE)
CUE is defined as the total Huperzine A amout excreted in urine during the whole study.
Time frame: Baseline、Day15-Day17
Urine excretion rate(UER)
URE is defined as the ratio of the Huperzine A dose excreted in the urine to the dose administered during the specific time period. It is calculated by the fomula: URE=UE/D×100%(D refers to the Huperzine A administration dose)
Time frame: Baseline、Day15-Day17
Cumulative urinary excretion rate(CUER)
CURE is defined as the summary of ratio of the Huperzine A dose excreted in the urine to the dose administered during the specific time period. It is calculated by the fomula: CURE=CUE/D×100%(D refers to Huperzine A administration dose).
Time frame: Baseline、Day15-Day17
Faeces excretion(FE)
FE is defined as the amout of the Huperzine A excreted in faeces during the whole study. It is calculated by the fomula: FE=Cf×Vf(Cf refers to concentration of Huperzine A in faeces, Vf refers to the volume of faeces).
Time frame: Baseline、Day15-Day17
Faeces excretion rate(FER)
FER is defined as the ratio of the Huperzine A doses excreted in the faeces to the dose administered.It is calculated by the fomula: FER=FE/D×100%(D refers to Huperzine A administration dose).
Time frame: Baseline、Day15-Day17
Metabolites of Huperzine A
To analyze the metabolites of Huperzine A by the plasma sample during the period of C and D methods administration and urine and faeces sample during the period of C method administration.(The methods of administration is explained in the detailed description)
Time frame: Day15、Day22
Number of participants with adverse events (AEs) or serious adverse events (SAEs) as assessed by NCI-CTCAE v5.0.
Time frame: Day1-Day28
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Jun 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Huperzine A
Wanbangde Pharmaceutical Group Co., LTD